■进行一项队列研究,比较射频消融(RFA)治疗单发T1aN0M0(T1a)和T1bN0M0(T1b)甲状腺乳头状癌(PTC)的治疗结果。
■这项回顾性分析包括310例接受RFA的低风险PTC患者,根据肿瘤大小分为T1a(n=272)和T1b(n=38)组。对两组的容积缩小率(VRR)进行比较分析,volume,局部肿瘤进展(LTP),和1:2倾向评分匹配(PSM)前后的无复发生存率(RFS)。进行了Cox分析,以检查几个变量的影响,包括T1b,PTCRFA后的复发。
■在整个26个月的中位随访期间,总VRR为99.99±0.11%,LTP的总发生率为2.58%(8/310)。RFA术后无不可恢复的并发症发生。PSM后T1a和T1b组之间的变化在体积方面不显著(p=0.574),VRR(p=0.574),完全消失率(p=0.210),LTP发生率(p=1.000),和RFS率(p=0.610)。T1b和LTP之间的相关性仍然不显著(p=0.686)。无远处转移或手术延迟。
■T1b的存在并不影响T1N0M0PTCRFA后患者的预后。经过适当的患者选择和充分的术前评估,RFA有可能作为T1a和T1bPTC患者的有效疗法。
To conduct a cohort
study comparing the treatment outcomes of radiofrequency ablation (RFA) therapy for solitary T1aN0M0 (T1a) versus T1bN0M0 (T1b) papillary thyroid carcinoma (PTC).
This retrospective analysis comprised 310 patients with low-risk PTC undergoing RFA classified into T1a (n = 272) and T1b (n = 38) groups according to the tumor size. A comparative analysis between the two groups was conducted for the volume reduction ratio (VRR), volume, local tumor progression (LTP), and recurrence-free survival (RFS) before and after 1:2 propensity score matching (PSM). Cox analysis was conducted to examine the influence of several variables, including T1b, on recurrence following RFA for PTC.
The total VRR was 99.99 ± 0.11% throughout the median follow-up duration of 26 months, and the overall incidence of LTP was 2.58% (8/310). No irrecoverable complications occurred after RFA. The variations between the T1a and T1b groups following PSM were insignificant in terms of volume (p = 0.574), VRR (p = 0.574), complete disappearance rate (p = 0.210), LTP incidence (p = 1.000), and RFS rate (p = 0.610). The correlation between T1b and LTP continued to be insignificant (p = 0.686). No distant metastasis or delayed surgery occurred.
The presence of T1b did not influence the patients\' prognoses following RFA for T1N0M0 PTC. After appropriate patient selection and adequate preoperative assessment, RFA has the potential to serve as an effective therapy for individuals with T1a and T1b PTC.